2024
Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy
Wang C, Chen L, Zhu J, Wang C, Li M, Miao Y, Liu N, Ji Z, Pan F, Liu Y, Zhu J, Yang Y, Chen Q. Programmable Bacteria‐Based Biohybrids as Living Biotherapeutics for Enhanced Cancer Sonodynamic‐Immunotherapy. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202316092.Peer-Reviewed Original ResearchSonodynamic therapyAntitumor immune responseTumor-associated antigensImmune memory responsePrevent tumor recurrenceInhibit tumor metastasisOrthotopic colorectal tumorsAbscopal effectTumor recurrenceEffective sonodynamic therapyTumor siteNano-sonosensitizersTumor hypoxiaPathogen-associated molecular patternsColorectal tumorsMemory responsesTherapeutic delivery systemsTumor metastasisImmune responseTumorLive biotherapeuticsMetastasisBacterial pathogen-associated molecular patternsMolecular patternsOverexpressing catalase
2023
Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer
Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, Zhu J, Zhang L, Wang Y, Fang H, Zhou J, Li M, Yang Y, Liu Z, Chen Q. Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer. Advanced Materials 2023, 35: e2306281. PMID: 37722134, DOI: 10.1002/adma.202306281.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeF. nucleatumTumor modelTherapeutic responseResponse to immune checkpoint blockadeColorectal cancerColorectal tumorsImmunosuppressive tumor microenvironmentColorectal cancer modelAnimal tumor modelsAgainst Colorectal CancerColorectal tumor cellsICB therapyCheckpoint blockadeCancer immunotherapyTumor microenvironmentFusobacterium nucleatumMC-38Cancer modelsTumor cellsClinical evidenceTumor developmentSide effectsTumorCancer treatmentDelivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance
Chen L, Zhao R, Kang Z, Cao Z, Liu N, Shen J, Wang C, Pan F, Zhou X, Liu Z, Yang Y, Chen Q. Delivery of short chain fatty acid butyrate to overcome Fusobacterium nucleatum-induced chemoresistance. Journal Of Controlled Release 2023, 363: 43-56. PMID: 37734673, DOI: 10.1016/j.jconrel.2023.09.028.Peer-Reviewed Original ResearchConceptsShort-chain fatty acid butyrateF. nucleatumFatty acid butyrateColorectal tumorsColorectal cancerInvasion of F. nucleatumTherapeutic efficacy of oxaliplatinEfficacy of oxaliplatinProgression of colorectal cancerEffect of butyrateOrthotopic colorectal tumorsFusobacterium nucleatumClinical application prospectsTherapeutic efficacyDrug resistanceIntravenous administrationColorectal cancer tissuesIntravenous injectionOral administrationCancer resistanceOral deliveryTumorKilling effectCancer tissuesChemoresistanceMolecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico
Perez-Mayoral J, Gonzalez-Pons M, Centeno-Girona H, Montes-Rodríguez I, Soto-Salgado M, Suárez B, Rodríguez N, Colón G, Sevilla J, Jorge D, Llor X, Xicola R, Toro D, Tous-López L, Torres-Torres M, Reyes J, López-Acevedo N, Goel A, Rodríguez-Quilichini S, Cruz-Correa M. Molecular and Sociodemographic Colorectal Cancer Disparities in Latinos Living in Puerto Rico. Genes 2023, 14: 894. PMID: 37107652, PMCID: PMC10138302, DOI: 10.3390/genes14040894.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerColorectal cancerCpG island methylator phenotypeMicrosatellite instabilityExact testColorectal cancer disparitiesSporadic colorectal cancerFisher's exact testMolecular carcinogenic pathwaysClinicopathologic featuresClinicopathological characteristicsCancer deathCancer disparitiesColorectal tumorsCarcinogenic pathwaysHispanic menMutation statusTumorsAdditional studiesMethylator phenotypeHispanic subpopulationsChi-squaredAmerindian admixtureMolecular pathwaysMolecular markers
2022
Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer
van den Driest L, Johnson CH, Rattray NJW, Rattray Z. Development of an Accessible Gene Expression Bioinformatics Pipeline to Study Driver Mutations of Colorectal Cancer. Alternatives To Laboratory Animals 2022, 50: 282-292. PMID: 35765262, DOI: 10.1177/02611929221107546.Peer-Reviewed Original ResearchConceptsColorectal cancerBioinformatics toolsExpression patternsKirsten rat sarcoma viral oncogene homologueNext-generation sequencing technologiesDifferential expression patternsCancer-related mortalityGenetic alterationsAdenomatous polyposis coliEffector proteinsMutational driversPrognostic significancePrognostic valueSequencing technologiesBioinformatics pipelinePatient prognosisGenetic dataB-RafColorectal tumorsNovel biomarkersColon cancerTherapeutic outcomesFrequency of mutationsAnatomical locationOncogene homologue
2019
Clinical and Pathological Characterization of Lynch-Like Syndrome
Picó MD, Castillejo A, Murcia Ó, Giner-Calabuig M, Alustiza M, Sánchez A, Moreira L, Pellise M, Castells A, Carrillo-Palau M, Ramon Y Cajal T, Gisbert-Beamud A, Llort G, Yagüe C, López-Fernández A, Alvarez-Urturi C, Cubiella J, Rivas L, Rodríguez-Alcalde D, Herraiz M, Garau C, Dolz C, Bujanda L, Cid L, Povés C, Garzon M, Salces I, Ponce M, Hernández-Villalba L, Alenda C, Balaguer F, Soto JL, Jover R. Clinical and Pathological Characterization of Lynch-Like Syndrome. Clinical Gastroenterology And Hepatology 2019, 18: 368-374.e1. PMID: 31220642, DOI: 10.1016/j.cgh.2019.06.012.Peer-Reviewed Original ResearchConceptsLynch-like syndromeColorectal cancerLynch syndromeFamily historyPathology featuresDiagnosis of CRCLynch syndrome-related tumorsDNA MMR deficiencyDNA mismatch repair deficiencyManagement of patientsFisher's exact testLoss of MSH2Mismatch repair deficiencyStudent's t-testMann-Whitney testBethesda criteriaPathology findingsMean agePathology characteristicsAmsterdam IGuideline criteriaUniversal screeningColorectal tumorsPatientsExact test
2017
Tu1974 Molecular Disparities and Kras Mutational Spectrum of Colorectal Tumors from Puerto Rican Hispanic Subjects
Marquez J, Pérez-Mayoral J, Gonzalez-Pons M, Rodriguez-Mañon N, Rivera-Lynch C, Soto M, Llor X, Xicola R, Lopez L, Torres-Torres M, Reyes J, Goel A, Torres-Cintrón C, Rodriguez-Quilichini S, Cruz-Correa M. Tu1974 Molecular Disparities and Kras Mutational Spectrum of Colorectal Tumors from Puerto Rican Hispanic Subjects. Gastroenterology 2017, 152: s1022. DOI: 10.1016/s0016-5085(17)33461-3.Peer-Reviewed Original Research
2016
Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis
Akintoye E, Kumar N, Aihara H, Nas H, Thompson C. Colorectal endoscopic submucosal dissection: a systematic review and meta-analysis. Endoscopy International Open 2016, 04: e1030-e1044. PMID: 27747275, PMCID: PMC5063641, DOI: 10.1055/s-0042-114774.Peer-Reviewed Original ResearchColorectal endoscopic submucosal dissectionEndoscopic submucosal dissectionR0 resectionResection rateAverage postoperative followR0 resection rateCurative resection rateFirst-line therapyAverage tumor sizeEn bloc resectionAdvanced endoscopic techniquesComprehensive literature searchMajor bleedingPostoperative followResection statusDelayed perforationClinical efficacyRecurrence rateSafety profileTumor sizeGastrointestinal tumorsTumor recurrenceSubmucosal dissectionColorectal tumorsEndoscopic techniquesIndividualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel
Sato KA, Hachiya T, Iwaya T, Kume K, Matsuo T, Kawasaki K, Abiko Y, Akasaka R, Matsumoto T, Otsuka K, Nishizuka SS. Individualized Mutation Detection in Circulating Tumor DNA for Monitoring Colorectal Tumor Burden Using a Cancer-Associated Gene Sequencing Panel. PLOS ONE 2016, 11: e0146275. PMID: 26727500, PMCID: PMC4699643, DOI: 10.1371/journal.pone.0146275.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAllelesCell Line, TumorColorectal NeoplasmsDNA Mutational AnalysisDNA PrimersDNA, NeoplasmFemaleGenes, NeoplasmHumansLeukocytes, MononuclearMaleMiddle AgedMultiplex Polymerase Chain ReactionPoint MutationPolymorphism, Single NucleotideSequence Analysis, DNATumor BurdenConceptsPeripheral blood mononuclear cellsTumor burdenColorectal tumorsVariant allele frequencyCurative resectionDroplet digital PCRPlasma DNACancer-associated genesTumor DNATumor burden monitoringUtility of ctDNABlood mononuclear cellsSingle nucleotide variantsGene sequencing panelAllele frequenciesMutation spectrumCancer patientsMononuclear cellsPrimary tumorCtDNA markersClinical utilityHealthy individualsSequencing panelGene point mutationsTumorsMicrosatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis
Koi M, Garcia M, Choi C, Kim H, Koike J, Hemmi H, Nagasaka T, Okugawa Y, Toiyama Y, Kitajima T, Imaoka H, Kusunoki M, Chen Y, Mukherjee B, Boland C, Carethers J. Microsatellite Alterations With Allelic Loss at 9p24.2 Signify Less-Aggressive Colorectal Cancer Metastasis. Gastroenterology 2016, 150: 944-955. PMID: 26752111, PMCID: PMC4808397, DOI: 10.1053/j.gastro.2015.12.032.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorChi-Square DistributionChromosome AberrationsChromosomes, Human, Pair 9Colorectal NeoplasmsDisease ProgressionDisease-Free SurvivalFemaleGenetic Predisposition to DiseaseHumansJapanKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsLoss of HeterozygosityMaleMicrosatellite RepeatsMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypeProportional Hazards ModelsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Republic of KoreaRisk FactorsTime FactorsTreatment OutcomeConceptsPrimary colorectal tumorsLoss of heterozygosityLiver metastasesColorectal cancerColorectal tumorsElevated microsatellite alterationsMicrosatellite alterationsStage IICurative treatment of patientsStage III colorectal cancerOverall survival of patientsSurvival of patientsIII colorectal cancerTumor to liverColorectal cancer recurrenceTreatment of patientsMatched liver metastasesCancer cell nucleiMatched metastasesDisease recurrenceOverall survivalPrognostic factorsAllelic lossNo significant differenceCurative treatment
2011
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma
Kostic A, Gevers D, Pedamallu C, Michaud M, Duke F, Earl A, Ojesina A, Jung J, Bass A, Tabernero J, Baselga J, Liu C, Shivdasani R, Ogino S, Birren B, Huttenhower C, Garrett W, Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Research 2011, 22: 292-298. PMID: 22009990, PMCID: PMC3266036, DOI: 10.1101/gr.126573.111.Peer-Reviewed Original ResearchConceptsColorectal carcinomaColorectal carcinoma pathogenesisColorectal tumorsCarcinomaTumor microenvironmentTumor/normal pairsNonneoplastic cellsCancer cellsWhole genome sequencesPrecise roleTumorsMicrobiotaRDNA sequence analysisQuantitative PCRFurther investigationComplex communitiesGenome sequenceGenomic analysisSequence analysisFirmicutes phylumFusobacteriaNormal pairsCellsDiverse collectionDNA pairs
2010
5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer
Jover R, Nguyen T, Pérez–Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás–Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A. 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology 2010, 140: 1174-1181. PMID: 21185836, PMCID: PMC3073650, DOI: 10.1053/j.gastro.2010.12.035.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntimetabolites, AntineoplasticChemotherapy, AdjuvantCohort StudiesColorectal NeoplasmsCpG IslandsDisease-Free SurvivalDNA MethylationFemaleFluorouracilFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsConceptsCpG island methylator phenotypeCIMP-positive tumorsAdjuvant chemotherapyColorectal cancerCIMP statusColorectal tumorsIndependent predictorsStage IITNM stage IIDisease-free survivalOnly independent predictorPopulation-based cohortResponse of patientsMedian followChemotherapySurvival timePatientsMLH1 promoterMultivariate analysisTumorsAbstractTextMicrosatellite instabilityCIMP-negative tumorsDFSMethylator phenotype
2006
Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma
Bellovin DI, Simpson KJ, Danilov T, Maynard E, Rimm DL, Oettgen P, Mercurio AM. Reciprocal regulation of RhoA and RhoC characterizes the EMT and identifies RhoC as a prognostic marker of colon carcinoma. Oncogene 2006, 25: 6959-6967. PMID: 16715134, DOI: 10.1038/sj.onc.1209682.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorCadherinsCell Line, TumorColonic NeoplasmsEnzyme ActivationEpithelial CellsHumansImmunohistochemistryImmunoprecipitationNeoplasm InvasivenessPrognosisPromoter Regions, GeneticProto-Oncogene Protein c-ets-1Reverse Transcriptase Polymerase Chain Reactionrho GTP-Binding ProteinsrhoA GTP-Binding ProteinrhoC GTP-Binding ProteinRNA, Small InterferingTranscription, GeneticConceptsColon carcinomaRhoC expressionPrognostic markerRhoC protein expressionE-cadherinET-1 binding sitesClinical outcomesPoor outcomeColon cancer cellsColorectal tumorsET-1Colon cancerUse of shRNAMesenchymal transitionExpression correlatesCarcinomaAberrant expressionHigh expressionProtein expressionCancer cellsMesenchymal characteristicsEMTSubsequent activationReciprocal regulationCell migration
2004
Colorectal tumors frequently express phosphorylated mitogen‐activated protein kinase
LEE S, LEE J, SOUNG Y, KIM S, NAM S, PARK W, KIM S, YOO N, LEE J. Colorectal tumors frequently express phosphorylated mitogen‐activated protein kinase. Apmis 2004, 112: 233-238. PMID: 15233637, DOI: 10.1111/j.1600-0463.2004.apm11204-0502.x.Peer-Reviewed Original ResearchConceptsMAP kinase/ERK kinaseColorectal tumorsMitogen-activated proteinWeak expressionDevelopment of colorectal tumorsNormal colon mucosaMitogen-activated protein kinaseVillous adenomaColonic mucosaTumorHuman malignanciesTubular adenomasEpithelial cellsPMEKERK kinaseProtein kinaseKinase pathwayAdenomasKinase
2000
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota M, Ohe-Toyota M, Ahuja N, Issa J. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Proceedings Of The National Academy Of Sciences Of The United States Of America 2000, 97: 710-715. PMID: 10639144, PMCID: PMC15395, DOI: 10.1073/pnas.97.2.710.Peer-Reviewed Original ResearchMeSH KeywordsAdenomaBase SequenceColorectal NeoplasmsCpG IslandsDNA MethylationDNA Mutational AnalysisDNA, NeoplasmGenes, p16Genes, p53Genes, rasHumansMicrosatellite RepeatsMutationPhenotypePoint MutationPolymorphism, Single-Stranded ConformationalProtein Serine-Threonine KinasesReceptor, Transforming Growth Factor-beta Type IIReceptors, Transforming Growth Factor betaSequence DeletionTumor Cells, CulturedConceptsCpG island methylator phenotypeColorectal cancerK-ras mutationsDifferent genetic lesionsActivation of oncogenesTumor suppressor geneMultiple CpG islandsColorectal tumorsMethylator phenotypeCpG islandsDistinct genetic profilesP53 mutationsEpigenetic alterationsMolecular diversitySuppressor geneGenetic lesionsNovel pathwayGroup of tumorsGenetic alterationsK-rasMutationsCancer developmentSimultaneous methylationGenes
1998
Loss of p120ctn in human colorectal cancer predicts metastasis and poor survival
Gold J, Reynolds A, Rimm D. Loss of p120ctn in human colorectal cancer predicts metastasis and poor survival. Cancer Letters 1998, 132: 193-201. PMID: 10397474, DOI: 10.1016/s0304-3835(98)00190-6.Peer-Reviewed Original ResearchConceptsColorectal cancerPrimary human colorectal adenocarcinomasHigher stage diseasePoor clinical outcomeHuman colorectal cancerHuman colorectal adenocarcinomaStage diseaseClinical outcomesNodal metastasisColorectal adenocarcinomaPoor survivalColorectal tumorsColon cancerImmunohistochemical methodsMetastasisReduced expressionCancerE-cadherinP120ctn expressionLoss of p120ctnFamily membersSurvivalPreliminary studyExpressionComplete loss
1992
Gastrin and colorectal cancer
Yapp R, Modlin I, Kumar R, Binder H, Dubrow R. Gastrin and colorectal cancer. Digestive Diseases And Sciences 1992, 37: 481-484. PMID: 1551333, DOI: 10.1007/bf01307566.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply